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Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder and cause 
of dementia and is characterized by amyloid plaques and neurofibrillary tangles. AD has 
traditionally been considered to primarily affect gray matter, but multiple lines of evidence 
also indicate white matter (WM) pathology and associated small-vessel cerebrovascular 
disease. WM glucose delivery and metabolism may have implications for local tissue 
integrity, and [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) may be 
helpful to assess neuroglial and axonal function in WM. Hypothesizing that affection of 
oligodendroglia will be associated with loss of glucose uptake, we aimed to investigate 
glucose metabolism in magnetic resonance imaging (MRI) white matter hyperintensities 
(WMHs) and normal-appearing WM in patients with and without evidence of amyloid 
plaques. Subjects with mild cognitive impairment or subjective cognitive decline were 
included and dichotomized according to pathological (Aβ+) or normal (Aβ−) concen-
trations of cerebrospinal fluid amyloid-β 1–42. A total of 50 subjects were included, of 
whom 30 subjects were classified as Aβ(+) and 20 subjects as Aβ(−). All subjects were 
assessed with MRI and FDG-PET. FDG-PET images were corrected for effects of partial 
voluming and normalized to cerebellar WM, before determining WMH FDG-uptake. 
Although there were no significant differences between the groups in terms of age, WMH 
volume, number of individual WMHs, or WMH distribution, we found significantly lower 
(p = 0.021) FDG-uptake in WMHs in Aβ(+) subjects (mean = 0.662, SD = 0.113) com-
pared to Aβ(−) subjects (mean = 0.596, SD = 0.073). There were no significant group 
differences in the FDG-uptake in normal-appearing WM. Similar results were obtained 
without correction for effects of partial voluming. Our findings add to the evidence for a 
link between Aβ dysmetabolism and WM pathology in AD.
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inTrODUcTiOn
Although traditionally considered two distinct entities, accumulating evidence links Alzheimer’s 
disease (AD) and cerebrovascular disease (CVD) (1). White matter (WM) hyperintensities (WMHs) 
of presumed vascular origin (2) are commonly recognized as markers of small-vessel CVD and 
have been associated with mild cognitive impairment (MCI) and AD (3, 4). ApoEϵ4 alleles, a 
FigUre 1 | inclusions and exclusions in the cohort. a5 subjects of >73 
or <44 years of age were excluded to limit between-group age differences. 
CSF, cerebrospinal fluid; Aβ, amyloid β-peptide; WMH, white matter 
hyperintensity.
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strong genetic determinant of AD risk, have been linked to both 
AD-related pathology (i.e., amyloid deposition) (5) and WMHs, 
particularly in extensive forms and combined with vascular risk 
factors (6, 7). However, the mechanisms linking the diseases 
remain unresolved (8).
Alzheimer’s disease is characterized by amyloid plaques and 
neurofibrillary tangles (9) formed by abnormal deposition of 
extracellular amyloid-β peptide (Aβ) and intraneuronal hyper-
phosphorylated tau, respectively. Also, vascular Aβ deposition 
(amyloid angiopathy) is present in the vast majority of subjects 
with AD (10). The concentration of Aβ in cerebrospinal fluid 
(CSF) decreases years before the appearance of clinical symptoms 
in AD (11), low levels being considered a key biomarker, and has 
high diagnostic accuracy for AD [reviewed in Blennow et  al. 
(12)]. Low CSF Aβ shows inverse correlations with positive amy-
loid positron emission tomography (PET) scans (13) and amyloid 
plaques demonstrated at autopsy (14), probably reflecting cortical 
Aβ deposition.
According to the amyloid cascade hypothesis (15, 16), Aβ 
dysmetabolism initiates the AD pathologic cascade resulting in 
neuronal loss and dysfunction, i.e., neurodegeneration. Cerebral 
hypometabolism, a neurodegenerative marker, results in reduced 
uptake of [18F]-fluorodeoxyglucose (FDG)-PET. In AD, mostly 
gray matter glucose metabolism has been studied; however, WM 
abnormalities are also common (17). Although vascular disease 
and WMHs have been associated with frontal hypometabolism 
(18), to our knowledge, no studies have investigated FDG-uptake 
in WM and WMHs in AD.
Demyelination and axonal rarefaction characterize WMHs, 
and we recently demonstrated reduced WMH tissue integrity 
in the presence of amyloid dysmetabolism, as measured by 
diffusion tensor imaging (19). With limited glycolytic capacity, 
axonal compartments depend on mitochondrial activity (20, 21). 
WM neuroglia metabolize glucose and subserve axonal energy 
requirements probably by way of lactate transfer (22), long-term 
energy deprivation leading to axonal dysfunction, neuronal 
death, and loss of oligodendrocytes (23, 24). Thus, WM glucose 
supply and uptake depends on neuroglial function, and FDG-
PET optimized for WM may be a helpful tool to assess WM 
function and integrity.
We hypothesized more pronounced hypometabolism within 
WMHs in amyloid-positive compared to amyloid-negative sub-
jects (here, defined by the level of CSF Aβ42). For comparison, 
we further analyzed FDG-PET uptake in normal-appearing white 
matter (NAWM).
MaTerials anD MeThODs
subjects
Subjects referred to a university hospital-based neurological 
outpatient memory clinic between 2005 and 2013 were routinely 
evaluated for study inclusion (Figure  1). Written informed 
consent was obtained from all participants prior to enrollment. 
Inclusion criteria were age 40–79  years, subjective cognitive 
complaints ≥6 months, and absence of dementia.
Included subjects were classified as MCI or subjective cogni-
tive decline (SCD) according to the Global Deterioration Scale 
(GDS) 2 or 3 (25, 26), as determined from clinical interview and 
screening tests: mini–mental state examination (MMSE) (27), 
the neurobehavioral cognitive status examination (Cognistat) 
(28), I-Flex (word fluency, interference, and numeral–letter 
items) (29, 30). SCD was defined as GDS 2, based on published 
cutoffs on the listed screening tests (≥28 for MMSE, <2 for 
I-Flex, above mild impairment on all the items of Cognistat). 
MCI was defined as GDS 3, based on scores below cutoff on one 
or more of the screening tests (30). Subjects classified as GDS 3/
MCI fulfill general criteria for MCI, as revised by Petersen et al. 
(31). The final diagnoses were established in consensus confer-
ences of physicians and neurologists at a university hospital. 
Participants with GDS >3 and clinical dementia rating >0.5 
(32) were considered demented, i.e., with evidence of significant 
impairment in activities of daily living, and excluded from the 
study. Subjects with a history of learning disabilities, established 
psychiatric comorbidity, anoxic brain damage, drug abuse, or 
solvent exposure were excluded. All participants had a standard-
ized clinical assessment including neurological examinations, 
magnetic resonance imaging (MRI), FDG-PET, and lumbar 
puncture.
Cerebrospinal fluid Aβ42 <710 ng/L was considered pathologi-
cal, or Aβ(+), according to our research criteria. This CSF Aβ42 
cutoff has recently been validated against Flutemetamol-PET 
(amyloid-PET) in an extension of the current cohort (Almdahl 
et al., 2016, submitted). Adding variance for measurement tech-
nique places the potential variance-dependent CSF Aβ42 cutoff 
above 710  ng/L. To avoid including false negatives (subjects 
with amyloid pathology) in the control [Aβ(−)] group, subjects 
with CSF Aβ42 levels between 710 and 850 ng/L were excluded. 
Subjects with CSF Aβ42 >850 ng/L were classified as Aβ(−) and 
used as a control group. For the present study, data were obtained 
from 50 subjects selected based on CSF Aβ42 <710 or >850 ng/L 
and WMH volume >350 mm3, of whom 29 were females and 
21 males, 30 Aβ(+), and 20 Aβ(−). Subjects with WMH vol-
ume <350 mm3 were excluded as we considered this to be the 
minimum volume required for valid analyses. Between-group 
FigUre 2 | co-registered structural Mri, WMh segmentation (cyan), and partial voluming uncorrected (a–D) and corrected (e–h) FDg-PeT images.
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age difference was limited by excluding subjects aged >73 and 
<44 years.
Based on the Norwegian Health and Research Act and the 
Helsinki Declaration, the study was approved by Regional 
Committee for Medical and Health Research Ethics, South East 
Norway.
Mri/FDg-PeT acquisition
Magnetic resonance imaging was performed using a Siemens 
Espree 1.5-T scanner. A 3D magnetization-prepared rapid gra-
dient echo (MP-RAGE) T1-weighted sequence was obtained 
(TR/TE/inversion time/flip angle = 2400/3.65/1000/8°, matrix =  
240 × 192, 160 sagittal slices, thickness  =  1.2  mm, in-plane 
resolution of 1 mm × 1.2 mm). A 2D axial fluid-attenuated inver-
sion recovery (FLAIR) image with the following parameters was 
obtained: TR/TE/TI = 13,420/121/2500, 36 slices, spaced at 3.0 
and 3.9 mm slice thickness.
Fluorodeoxyglucose-PET/CT imaging was performed with 
a Siemens Biograph 16 PET/CT scanner. All subjects fasted at 
least 4 h before image acquisition and received a bolus injection 
of 218 MBq (±23 MBq) FDG tracer followed by 45 min of rest 
before being positioned head-first supine in the scanner. Prior 
to the PET acquisition, a low-dose CT scan for attenuation 
correction was acquired. Patients were scanned for 15  min in 
3D mode using one bed position (axial range = 16 cm). Data 
were corrected for random events, dead time, attenuation 
(CT-derived μ-map), scatter (model based), and decay. PET 
volumes were reconstructed using an iterative algorithm (OSEM 
2D, four iterations, eight subsets), and a post-reconstruction 
3D Gaussian filter 3.5  mm full-width half maximum was 
applied. The axial image format was 256  ×  256 (pixel size: 
2.67 mm × 2.67 mm), with a slice thickness of 2.00 mm. Blood 
glucose at FDG injection time was measured routinely, and the 
subject was excluded if blood glucose concentration exceeded 
8.0 mmol/L.
image Processing
Measurement accuracy of PET imaging tracer uptake may be 
limited by a relatively poor scanner resolution and by reconstruc-
tion algorithm, resulting in partial voluming effects (i.e., spillover 
effect from high to adjacent low [18F] FDG-uptake regions). To 
adjust for this, and to obtain correct quantification of glucose 
metabolism (i.e., FDG-PET uptake), we recently developed a 
partial voluming correction method, applied herein (33). Whole 
head PET volumes were co-registered to the anatomical volume 
using a 6-parameter rigid body spatial registration as imple-
mented in the Spatial Parametrical Mapping (SPM 8, Wellcome 
Trust Centre for Neuroimaging, UCL, UK) co-registration tool. 
PET volumes were resliced into 1 mm MRI space using a spline 
interpolation. For each subject, a voxel-based intensity normali-
zation to the mean uptake in the cerebellar WM was performed. 
(Prior to intensity normalization, the cerebellar WM mask was 
eroded to avoid effects of partial voluming, inaccurate segmenta-
tion, or co-registration.) Intensity normalized volumes were used 
for all further analyses.
Further, the FDG-PET and structural images were 
 co- registered to high-resolution 3D T1-weighted MRI scans for 
WMH segmentation and measurements (Figure  2). FDG-PET 
analyses and calculations were performed using The Oxford 
Centre for Functional MRI of the Brain (FMRIB) Software 
Library (FSL) version 5.0 (34, 35).
A recently developed in-house object-based supervised 
machine-learning algorithm was used for automated segmen-
tation and quantification of WMHs based on FLAIR image 
intensity and masks of tissue types (36). All segmentations were 
manually inspected for accuracy and edited when necessary. For 
each subject, the number of non-interconnected hyperintense 
areas was further determined, as well as periventricular WMH 
volume (≤10 mm from the ventricles). The reconstruction and 
segmentation of WM was performed with the FreeSurfer image 
analysis suite version 5.3.0 (http://surfer.nmr.mgh.harvard.edu/). 
TaBle 1 | Demographic and clinical data.
aβ(+) (n = 30) aβ(−) (n = 20) p-Value  
(aβ+ vs. aβ−)
Age, years 63.77 (6.99) 59.85 (7.29) 0.062a
Women/men, n 19/11 10/10 0.349b
MMSE 27.70 (1.34) 28.15 (1.50) 0.254c
SCD/MCI diagnoses, 
n (%)
3 (10.0)/27 (90.0) 4 (20.0)/16 (80.0) 0.281b
CSF Aβ42, ng/L 521.07 (133.23) 1036.80 (120.82) <0.001a,*
WMH volume, mm3 5542.76 (7321.89) 3345.38 (5063.31) 0.291a,d
Values are given in mean (SD) unless otherwise indicated.
aCalculated using independent-samples T-test.
bCalculated using Pearson chi-square test.
cCalculated using Mann–Whitney U test.
dp-Value for log transformed WMH volume adjusted for age.
*Significant difference between the two groups.
CSF, cerebrospinal fluid; Aβ, amyloid β-peptide; WMH, white matter hyperintensity; 
MMSE, mini-mental state examination; MCI, mild cognitive impairment; SCD, subjective 
cognitive decline.
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NAWM was defined by subtracting WMH from the total WM. 
FDG-PET measurements in NAWM were extracted using FSL.
cerebrospinal Fluid analysis
Lumbar puncture was performed consecutively after inclusion, 
in the L3/L4 or L4/L5 interspace at a standardized time of day 
(around noon). CSF samples were examined for levels of Aβ42, 
total microtubule-associated protein Tau (T-tau), and Tau phos-
phorylated at threonine 181 (P-tau) with commercially avail-
able enzyme-linked immunosorbent assay kits (Innogenetics, 
Belgium, presently Fujirebio Europe).
The procedure was carried out in accord with the manu-
facturers’ procedures at the national reference laboratory for 
these tests at the Department of Interdisciplinary Laboratory 
Medicine and Medical Biochemistry, Akershus University 
Hospital. Although measurements of CSF AD biomarkers show 
between-laboratory and batch-to-batch assay variability (37), the 
national reference laboratory is part of the European multicenter 
project “Biomarkers for Alzheimer’s disease and Parkinson’s 
disease” (BIOMARKAPD), funded by EU Joint Programme-
Neurodegenerative Disease Research (JPND), for standardiza-
tion of analytical methods and laboratory procedures to increase 
its accuracy with regard to CSF biomarkers of neurodegenerative 
diseases.
statistical analysis
Group differences in demographic and clinical features were 
assessed using χ2 tests for categorical data and independent-
samples T-test or Mann–Whitney U test for continuous data. The 
WMH volume distribution was skewed and therefore logarithmi-
cally transformed prior to this analysis.
FDG-PET Uptake Differences in WMHs
The partial voluming corrected FDG-PET signal in WMHs was 
log-transformed prior to regression to meet the assumptions of 
linear regression and then adjusted for age and WMH volume. 
The ensuing residuals were normally distributed (as assessed 
by the Kolmogorov–Smirnov test and visual inspection of the 
histograms) and therefore used for further statistical analyses. 
Conducting independent-samples T-test, we compared group 
differences (i.e., Aβ+ vs. Aβ−) in PET signal in WMHs with a 
significance level set at p < 0.05.
Associations between Potential Confounders and 
FDG-PET Uptake in WMHs
Linear regression analyses were carried out for both groups (i.e., 
Aβ+ and Aβ−). Using linear regression, we analyzed potential 
effects of the presence of ApoEϵ4 alleles. Although included as 
covariates in our main analyses, we further analyzed the effects 
of age and WMH volume on the FDG-PET signal in WMHs 
by means of linear regression with the FDG-PET signal as the 
dependent variable, and age and WMH volume as independent 
variables. In a separate linear regression model, sex was also 
included to assess potential associations with the FDG-uptake in 
WMHs.
WMH Location and Size
To assess whether our results could be influenced by group 
differences in WMH location (periventricular vs. subcortical) 
or individual WMH size, we determined the mean size of the 
per-subject of non-interconnected WMHs and the periventricu-
lar WMH volume. The volume measures were log-transformed 
prior to analyses. Individual mean WMH sizes were adjusted 
for age and total WMH volume, and the resulting residuals were 
normally distributed (assessed by the Kolmogorov–Smirnov test 
and inspection of histograms). We were unable to adjust perive-
ntricular WMH volume for both age and total WMH volume 
because this analysis did not fulfill the assumptions of regression, 
i.e., the resulting residuals were not normally distributed. We 
therefore adjusted periventricular WMH volume for age (with 
resultant normally distributed residuals). Group differences were 
assessed with independent-samples T-test with a significance 
level of p < 0.05.
FDG-PET Uptake in NAWM
In comparison to effects in WMHs, we analyzed the FDG-PET 
signal in NAWM. The FDG-PET signal was adjusted for age and 
WMH volume by a linear regression model, and the resulting 
residuals were normally distributed as assessed by Kolmogorov–
Smirnov test and visual inspection of histograms. Conducting an 
independent-samples T-test, we compared FDG-PET signal in 
NAWM between the Aβ(+) and Aβ(−) group. Significance was 
determined by a p-value < 0.05.
All statistical analyses were performed with SPSS version 22 
(SPSS Inc., Chicago, IL, USA).
resUlTs
Demographic and clinical data are shown in Table 1. Analyses 
revealed neither statistically significant group differences in 
terms of sex, age, or WMH volume nor were there significant 
group differences in terms of diagnoses (SCD/MCI).
FigUre 3 | example of an amyloid-positive (a) vs. amyloid-negative 
(B) subject and the corrected FDg-PeT images, WMh segmentation 
(color), and the metabolic profile (red line) for the selected WMh 
section across the brain. The color bar indicates normalized relative 
uptake.
FigUre 4 | illustration of corrected (a) and uncorrected (B) images for effects of partial voluming. WMHs PET intensities and the metabolic profile for the 
selected WMH section across the brain shown in (c).
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FDg-PeT Uptake Differences in WMhs
To investigate the effects of amyloid pathology on WMH glucose 
uptake, we analyzed the FDG-PET signal in WMHs in Aβ(+) 
and Aβ(−) subjects (Figure 3). Including potential confounders 
such as age and WMH volume, analyses of normalized, partial 
voluming corrected FDG-PET signal in WMHs revealed sig-
nificantly reduced activity (p = 0.021) in Aβ(+) (mean = 0.596; 
SD  =  0.073) relative to Aβ(−) (mean  =  0.662, SD  =  0.113). 
Cohen’s effect size value (d = −0.67) indicates moderate to high 
effect. Inclusion of ApoEϵ4-status as an additional covariate 
did not alter the findings. Our findings were also consistent 
in additional analyses without adjustment for age and WMH 
volume. When analyzing the uncorrected FDG-PET signal (i.e., 
without correcting for effects of partial voluming), adjusted for 
age and WMH volume, the significant results were consistent, 
i.e., significant difference (p =  0.014) when comparing Aβ(+) 
(mean = 0.598, SD = 0.074) and Aβ(−) subjects (mean = 0.676, 
SD  =  0.113). Although consistent between-group differences 
were observed using uncorrected FDG-PET images, the intensity 
profiles differ slightly between corrected and uncorrected PET 
images (Figure 4).
associations between Potential 
confounders and FDg-PeT Uptake  
in WMhs
We investigated potential bias by performing linear regres-
sion analyses with different potential confounders. Results are 
summarized in Table 2. Linear regression analyses revealed no 
TaBle 2 | effects of age, WMh volume, and apoe on the FDg-PeT 
uptake in WMhs.
independent 
variables
Dependent variables
FDg-PeT uptake in WMhs
aβ(+) aβ(−)
Beta p R2 Beta p R2
WMH volume 0.187 0.369 0.030 −0.278 0.259 0.075
Age −0.071 0.732 0.069 0.776
WMH volume 0.133 0.533 −0.269 0.301
Age −0.054 0.795 0.067 0.064 0.800 0.076
Sex 0.198 0.322 0.034 0.895
WMH volume 0.138 0.500 −0.353 0.177
Age −0.041 0.842 0.063 0.072 0.767 0.126
ApoE4 0.20 0.300 −0.24 0.351
Associations between age, WMH volume, and ApoE, and the WMH FDG-PET uptake 
were determined by means of linear regression.
FDG-PET, [18F]-fluorodeoxyglucose positron emission tomography; WMH, white matter 
hyperintensity; Aβ, amyloid β-peptide; ApoE4, apolipoprotein E4.
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significant effect of sex, age, or WMH volume on the FDG-PET 
signal in WMHs in neither of the groups. Therefore, we did not 
correct for sex in our analyses. Using age and WMH volume as 
covariates, linear regression analyses further revealed no signifi-
cant associations between ApoEϵ4-status and WMHs FDG-PET 
uptake in Aβ(+) or Aβ(−).
WMh location and size
We compared the WMH location and individual WMH size, as 
these factors could affect the primary analysis. With age and total 
WMH volume as covariates, we found no significant differences 
when comparing the mean per-subject size of individual WMHs 
(p =  0.545) of the Aβ(+) (mean =  101  mm3, SD =  67  mm3) 
and Aβ(−) (mean =  75  mm3, SD =  28  mm3) groups. In addi-
tion, when corrected for age, analyses of the periventricular 
WMH volume did not reveal significant differences (p = 0.117) 
between Aβ(+) (mean = 4942 mm3, SD = 6611 mm3) and Aβ(−) 
(mean = 2639 mm3, SD = 3532 mm3). These results were consist-
ent also without adjustment for covariates.
FDg-PeT Uptake in naWM
The normalized FDG-PET signal in NAWM in both groups 
was further analyzed in comparison to the uptake in WMHs. 
Using age and WMH volume as covariates, we found no 
significant differences (p =  0.296) in NAWM when comparing 
Aβ(+) (mean = 0.910, SD = 0.059) and Aβ(−) (mean = 0.929, 
SD =  0.066). Although the FDG-PET signal was lower in the 
Aβ(+) group, the results remained non-significant also without 
adjusting for age and WMH volume.
DiscUssiOn
To our knowledge, we are the first to assess the FDG-PET signal 
within WMHs and also the association with amyloid pathology. 
The present results support an association between amyloid 
dysmetabolism and WMHs, as the lowest WMH metabolism is 
seen in cases with amyloid pathology. This was not encountered 
in NAWM and may therefore be construed as specific for WMHs.
Cortical hypometabolism associated with WMHs differs from 
the temporoparietal pattern typically seen in AD (18, 38). It has 
been suggested that the association between WMHs and cerebral 
hypometabolism reflects synaptic hypoactivity (i.e., diaschisis) as 
a result of CVD, rather than being related to amyloid pathology 
(39). However, in the present study, Aβ(+) subjects had signifi-
cantly lower FDG-PET signal within WMHs compared to Aβ(−) 
subjects, suggesting a link between amyloid dysmetabolism and 
glucose utilization and metabolism. While ApoEϵ4 alleles are 
associated with AD and WMHs, this relationship appears to be 
more prominent in late-stage cases, whereas the present results 
suggest that amyloid is more related to initial WMH severity in 
terms of affected metabolism (7, 40).
The pathogenic interactions between CVD and AD are 
complex, and the exact mechanisms remain unclear. It has been 
hypothesized that vascular risk factors and resulting vascular 
injury, lead to cerebral hypoperfusion and impair the blood–
brain barrier function (41). Consequently, acceleration of Aβ 
production and impairment of its clearance may occur, leading 
to Aβ accumulation. However, associations between CVD and 
AD are observed also in populations without substantial vascular 
comorbidities (42), supporting an underlying heterogeneity of 
WMHs in AD, i.e., not only related to vascular factors and small-
vessel CVD.
Conversely, Aβ may be involved in the vascular alterations 
observed in AD, as hypothesized herein. Cerebral amyloid 
angiopathy (CAA), characterized by amyloid deposits in lep-
tomeningeal and cortical arteries and arterioles are associated 
with WMHs (43). CAA and ischemic brain injury coexist (44), 
and studies have shown that WMHs in AD (3), as well as in CAA 
(45, 46), have a predominant posterior cerebral distribution. 
Therefore, it is possible that vessel wall amyloid deposits may 
compromise perfusion and WMH metabolism in cases with low 
CSF Aβ.
Microscopically, the cerebral vasculature in AD presents with 
several pathological changes: degeneration of endothelial cells 
and surrounding pericytes, thickening of the capillary basement 
membrane, and, as the disease progresses, the cerebral blood 
flow (CBF) decreases (47). As glucose delivery and utilization are 
tightly coupled to regional CBF (48), CBF reduction may result in 
concurrently reduced glucose supply. The findings of more pro-
nounced hypometabolism in the presence of amyloid pathology 
may therefore potentially result from amyloid-related hypoperfu-
sion, and consequently hypometabolism, within WMHs.
The current findings are in line with our early work estab-
lishing associations between low CSF Aβ42 and WMHs, and 
also with our recently published data using MRI diffusion 
parameters to study WMH tissue integrity (19, 49). The latter 
data imply impaired microstructural integrity in WMHs in 
the presence of amyloid dysmetabolism, suggesting more pro-
nounced oligodendroglial and axonal damage in the presence 
of amyloid pathology (19). Reduced glucose uptake in Aβ(+) 
subjects illustrate that WMH glucose metabolism is similarly 
affected, relating to impaired function of the WM components 
including neuroglia (22).
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Patient cases at the SCD and MCI stages are etiologically het-
erogenous, also differing in FDG-uptake (50). However, subject 
selection to the current study is based on the CSF Aβ42 level and 
not on clinical diagnoses. Although the cortical FDG-PET signal 
in general may be lower in MCI, the proportion of SCD and MCI 
cases in the two study groups was similar, reducing a potential 
impact on our results. Therefore, and also to avoid overadjust-
ment, patient stage was not included as a covariate in the current 
study.
Different spatial distribution of WMHs could be a potential 
bias. However, this was investigated in the same study population 
in a previous work (19), and no statistically significant group dif-
ferences were observed in either of the cerebral lobes (i.e., frontal, 
parietal, temporal, occipital lobes) or cingulate. Although the 
phenomenon of WMH penumbra was recently described (51), 
as microstructural alterations were observed also in the vicinity 
of areas of definite WMHs, these areas was not included in our 
analyses but may be of interest for future studies.
The WMHs FDG-PET intensities are slightly different 
when comparing partial voluming corrected and uncorrected 
intensities (Figure  3), although the between-group differences 
are consistent. While the uncorrected images show a gradual 
metabolic reduction from the cortex toward the deeper brain 
regions, the corrected intensity profile demonstrates a clear-cut 
reduction corresponding to tissue borders (as the gray/WM 
border), probably giving a closer approximation to the actual 
cerebral metabolism. This shows that applying partial voluming 
correction methods, as herein, enables the use of optimized PET 
images (i.e., partial voluming corrected images) also for WM and 
WMHs analyses.
Although correction for effects of partial voluming was carried 
out, limitations relating to FDG-PET must also be considered 
when interpreting the results. Spillover from the ventricles 
could occur due to the large contrast between the WM and the 
ventricles; however, no statistically significant group differences 
in periventricular WMH volume were observed. In addition, in 
both groups there was a strong positive correlation (r > 0.960, 
p < 0.001) between periventricular WMH volume and the total 
WMH volume (a covariate in our analyses), in effect also control-
ling for this. Furthermore, while smaller individual WMHs may 
be more vulnerable to spillover from the presumptively higher 
FDG-uptake NAWM, we found no significant group differences 
in the mean size of the individual non-interconnected WMH 
size. As such, we consider the bias relating to these factors to be 
reduced.
Age, strongly related to WMHs, and WMH volume may 
impact on the present results, and these factors were included 
as covariates to remove potential bias. However, their effect on 
the FDG-PET signal in WMHs was non-significant, which is in 
line with our observations with diffusion tensor imaging (19). 
Hence, it is less likely our results are biased by these factors and 
the FDG-PET signal in WMHs may rather be influenced by 
amyloid-related pathology, as suggested here.
Both our earlier findings of Aβ pathology-associated reduced 
WMH structural integrity and the present findings of reduced 
WMH glucose metabolism implicate neuroglia and oligo-
dendrocyte pathology, which could be induced by Aβ-related 
capillary pathology as described above. However, cortical and 
intraneuronal Aβ pathology could also induce neuronal and 
mitochondrial pathology (52), a downstream effect on neuroglia 
putatively making WM elements susceptible to cerebrovascular 
pathology in AD cases. Neuropathological and in vivo perfusion 
and amyloid imaging studies could serve to distinguish these 
hypotheses.
The limitations mentioned, together with a relatively small 
sample size in the current study, necessitate that findings are rep-
licated in larger cohorts, and future studies are also warranted to 
further establish mechanisms linking Aβ pathology and WMHs. 
However, the current findings add to the pool of evidence link-
ing CVD and AD pathomechanistically and may reflect the 
heterogeneity of the WMH etiopathology in AD, involving both 
Aβ pathology and small-vessel CVD.
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